Bioceltix Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	38.2	9.31	4.12	6.05
Cash & Short-Term Investments	38.2	9.31	4.12	6.05
Cash Growth	163.76%	125.98%	-31.96%	-
Accounts Receivable	0	0	0	-
Other Receivables	3.46	1.88	0.23	0.44
Receivables	3.46	1.88	0.23	0.44
Inventory	0.01	0.01	-	-
Prepaid Expenses	-	0.01	0.01	0.01
Other Current Assets	-	0	1.67	0.01
Total Current Assets	41.68	11.21	6.02	6.51
Property, Plant & Equipment	2.28	1.48	1.46	1.53
Long-Term Deferred Tax Assets	0.02	0.04	0.03	0.02
Other Long-Term Assets	0.41	-	0.14	0.14
Total Assets	44.39	12.74	7.65	8.2
Accounts Payable	1.14	1.21	0.96	0.29
Accrued Expenses	0.48	0.44	0.34	0.19
Current Portion of Leases	0.78	0.1	0.12	0.38
Current Income Taxes Payable	0.28	0.36	0.27	0.12
Current Unearned Revenue	0.01	0.03	0.56	0.93
Total Current Liabilities	2.69	2.14	2.25	1.91
Long-Term Leases	0.17	0.08	0.18	0.15
Long-Term Unearned Revenue	-	-	0.03	0.06
Long-Term Deferred Tax Liabilities	0.09	0.04	0.04	0.07
Total Liabilities	2.96	2.27	2.5	2.2
Common Stock	0.49	0.41	0.34	0.33
Additional Paid-In Capital	52.82	23.8	14.44	15.14
Retained Earnings	-11.88	-13.74	-13.99	-9.47
Comprehensive Income & Other	-	-	4.36	-
Shareholders' Equity	41.43	10.47	5.15	6
Total Liabilities & Equity	44.39	12.74	7.65	8.2
Total Debt	0.95	0.18	0.29	0.53
Net Cash (Debt)	37.25	9.14	3.83	5.52
Net Cash Growth	160.89%	138.76%	-30.74%	-
Net Cash Per Share	9.12	2.33	1.15	1.75
Filing Date Shares Outstanding	4.92	4.13	3.98	3.29
Total Common Shares Outstanding	4.92	4.13	3.43	3.29
Working Capital	38.99	9.07	3.78	4.61
Book Value Per Share	8.41	2.53	1.50	1.82
Tangible Book Value	41.43	10.47	5.15	6
Tangible Book Value Per Share	8.41	2.53	1.50	1.82
Buildings	0.33	0.33	0.33	0.33
Machinery	0.27	0.27	0.24	0.25

Source: S&P Capital IQ. Standard template. Financial Sources.